PVC (polyvinyl chloride) medical devices — IV tubing, blood bags, dialysis tubing, enteral feeding tubes, and nasogastric tubes — require plasticisers to remain flexible, and DEHP (di(2-ethylhexyl) phthalate) has been the plasticiser of choice in medical-grade PVC for six decades because it provides ideal flexibility at the required concentrations (30–40% by weight). DEHP is not chemically bonded to the PVC polymer — it leaches freely into any fluid the tubing contacts. Blood transfusion patients, premature infants in neonatal intensive care units, and dialysis patients receive DEHP doses that measurably exceed general population background levels. Neonatal intensive care is the highest-exposure scenario: critically ill premature infants may receive multiple IV lines, nasogastric tubes, and respiratory tubing simultaneously, with DEHP leaching into all of them.
Where it's found
IV administration sets (drip tubing) and associated bags used in all hospital IV treatments. Blood storage bags and transfusion sets — DEHP migrates from the PVC bag walls into stored blood. Haemodialysis tubing used in kidney dialysis — dialysis patients receive the highest cumulative medical DEHP doses. Enteral (nasogastric) feeding tubes and associated feeding bags. Respiratory equipment tubing including CPAP and ventilator circuits. Neonatal and paediatric IV tubing and nasogastric feeding equipment. The total DEHP load delivered to a patient correlates directly with the duration of treatment and the number of PVC devices in simultaneous use.
Routes of exposure
Direct intravenous infusion of DEHP leached into IV solutions is the most bioavailable route — DEHP delivered intravenously bypasses all first-pass metabolism and distributes directly to tissues. Blood transfusion delivers DEHP stored in PVC blood bags. Enteral administration via DEHP-leaching feeding tubes. DEHP leaching rate increases with: lipid content of the infused fluid (fat-soluble DEHP migrates into lipid-containing solutions fastest), temperature, flow rate, and duration of contact. Premature infants receiving total parenteral nutrition (TPN) via PVC tubing receive the highest weight-adjusted DEHP doses of any patient group.
Health concerns
DEHP is an anti-androgenic endocrine disruptor that impairs testosterone synthesis in Leydig cells — this is most concerning during male reproductive system development. Animal studies show that DEHP exposure during the critical masculinisation programming window (8–12 weeks gestation in humans) causes a syndrome of reproductive abnormalities including hypospadias, cryptorchidism, and reduced testosterone. Epidemiological studies have found associations between maternal DEHP exposure and male genital malformations and altered anogenital distance (a sensitive marker of androgen disruption) in infant sons. In premature infants in NICU, DEHP exposure from multiple medical devices is among the highest DEHP exposures documented in the human population.
Evidence
DEHP anti-androgenic activity and reproductive developmental toxicity is established from animal studies and supported by human epidemiological data. DEHP migration from medical PVC into IV solutions and blood is analytically documented. The specific health consequences of medical DEHP exposure in preterm infants are an active research area — biomonitoring studies confirm very high DEHP body burden in NICU patients, but controlled trials comparing DEHP-free versus DEHP-containing medical devices on long-term developmental outcomes are logistically difficult. EU restriction of DEHP in medical devices was implemented in 2010 for high-risk patient categories; full transition to DEHP-free alternatives is progressing.
Who's most at risk
Premature infants in neonatal intensive care receiving multiple simultaneous PVC device exposures — this is the highest-risk population. Male infants during the masculinisation programming window (first trimester exposure) are most vulnerable to anti-androgenic reproductive effects. Dialysis patients with chronic repeated DEHP exposure from dialysis tubing over months to years. Trauma and intensive care patients receiving large-volume IV therapy over extended periods.
Regulatory status
RegulationEU REACH Restriction (Annex XVII, Entry 51) restricts DEHP in medical devices intended for use in procedures on vulnerable populations (neonates, male infants, pregnant and breastfeeding women) to 0.1% from January 2015, with a requirement for safety justification or DEHP-free alternatives. The UK retained equivalent restrictions post-Brexit. The EU Medical Devices Regulation (MDR) 2017/745 requires manufacturers to justify the use of substances of concern including phthalates. Citrate-plasticised PVC (using ATBC — acetyl tributyl citrate) and non-PVC alternatives (polyolefins, polyurethane) are available for most medical device applications.
How to reduce your exposure
Healthcare providers can request DEHP-free medical devices — these are available for virtually all applications and are mandated for high-risk patients under REACH. Patients can ask healthcare providers whether DEHP-free alternatives are being used for prolonged IV treatments. For the general public: awareness that medical DEHP exposure is proportional to treatment duration — routine brief IV treatments in adults pose lower risk than prolonged or repeated treatments. Parents of premature babies can advocate for DEHP-free neonatal devices.
The nutrition connection
DEHP's anti-androgenic activity involves inhibition of testicular steroidogenesis — specifically, it reduces expression of StAR (steroidogenic acute regulatory protein), the rate-limiting step in testosterone synthesis. Adequate zinc is required for 17β-hydroxysteroid dehydrogenase, which catalyses the final step of testosterone synthesis that DEHP impairs. Dietary adequate zinc from shellfish, red meat, and seeds supports testicular steroidogenesis. Omega-3 fatty acids reduce systemic inflammation relevant to DEHP's metabolic effects. Antioxidants (vitamin E, selenium) protect testicular cells from the oxidative stress component of DEHP toxicity.